iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a woman’s breast anatomy from the mammogram image.
Símbolo de cotizaciónICAD
Nombre de la empresaICAD Inc
Fecha de salida a bolsaDec 13, 1984
Director ejecutivoMs. Dana R. Brown
Número de empleados66
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 13
Dirección98 Spit Brook Rd Ste 100
CiudadNASHUA
Bolsa de valoresEuronext Paris
PaísUnited States of America
Código postal03062-5737
Teléfono16038825200
Sitio Webhttps://www.icadmed.com/
Símbolo de cotizaciónICAD
Fecha de salida a bolsaDec 13, 1984
Director ejecutivoMs. Dana R. Brown
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos